Multistage microrobots with pH-responsive release of platelet membrane-coated nanoparticles

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Not reported in abstract — no quantitative effect size data available

• Primary Outcome: Increased nanoparticle retention at colon cancer cell targets and enhanced cancer cell cytotoxicity in an in vitro model incorporating flow, pH variation, and villi-like structures, compared to nanoparticles administered alone

• Nnt Or Sensitivity: Not applicable at this preclinical stage — no NNT, sensitivity, specificity, or hazard ratio calculable. Relative improvement in nanoparticle retention and cytotoxicity described qualitatively only

• Confidence Interval: Not reported

Clinical Application

Clinical feasibility is currently very low. Significant barriers include: requirement for external magnetic field infrastructure (not available in standard clinical settings), regulatory approval pathway for a complex combination medical device/drug product, manufacturing standardisation of platelet membrane-coated nanoparticles at scale, demonstration of safety in living organisms, and health economic justification. A realistic clinical translation timeline, if successful, would be 10–15 years minimum Colorectal cancer is the second most commonly diagnosed cancer in Australia, with approximately 15,500 new cases annually (Cancer Australia data). The therapeutic target is therefore highly clinically relevant to the Australian healthcare context. However, this platform is not PBS-listed, not TGA-approved, and has no current pathway to clinical use in Australia. RACGP and gastroenterology guidelines currently recommend standard chemotherapy regimens (FOLFOX, FOLFIRI, capecitabine) for colorectal cancer. This research represents basic science that may inform future therapeutic development but has no immediate implications for Australian clinical practice or prescribing. Australian researchers and clinicians should monitor this field as it progresses through preclinical development. Not currently applicable to any clinical population. The intended future target population would be patients with gastrointestinal malignancies, particularly colorectal cancer, who require localised drug delivery to overcome systemic toxicity limitations of conventional chemotherapy

Abstract

Targeted drug delivery in the gastrointestinal tract remains challenging because therapeutics must overcome multiple hierarchical barriers before reaching diseased tissue. Here, we present a multistage delivery platform that integrates magnetic microrobots, a pH-responsive protective coating, and platelet membrane-coated nanoparticles (PNPs) in one platform. A fillable design enables the formation of an internal magnetic layer for microrobot actuation, while the pH-responsive coating protects the cargo during transit and selectively degrades upon pH change, releasing cancer cell-targeting PNPs. In an in vitro colon cancer model that reproduces key gastrointestinal features, including flow, pH variation, and villi-like structures, this strategy increased nanoparticle retention and enhanced cancer cell cytotoxicity compared to nanoparticles administered alone. Ex vivo studies in porcine stomach and intestine further demonstrated robust locomotion on compliant and folded tissue surfaces. These results establish an environment-responsive hierarchical delivery strategy for more precise oral delivery in complex gastrointestinal settings.

References

1. 1.Sun, R., Kim, J., Leng, Y., Zuo, Y., Kim, J., Xie, R., Yang, T., Ma, L., Song, X., Ma, J., Joo, J., Cho, Y.-K., & Stevens, M. M. (2026). Multistage microrobots with pH-responsive release of platelet membrane-coated nanoparticles. Science Advances. https://doi.org/10.1126/sciadv.aee6534